Blog / Archives
Rayno SnowBlog: LaNina Strengthens, Nat Gas Gets Weather Boost
Nat Gas Approaches Breakout at $4.50 Cold weather is forecasted for the NE and SE for the next 10 days giving a boost to nat gas prices reaching a five day high near $4.50 today. November price...
Time to Buy Drug Stocks for Yield: ABT,BMY,NVS
Contrarian Call -Look at the Drug Stocks The healthcare sector has lagged the market in 2010 down about 1.34% compared to the S&P up about 9%. The large cap drug sector has done worse down 4.3%....
Rayno Life Science Portfolio: Seracare (SRLS) Surges 11% on Earnings
SeraCare Reports 40% Increase in Net Income Over Prior Year SeraCare (SRLS) executed six consecutive quarters of successful growth with revenue growth of 13% to $50.4 M for the fiscal year ending...
Vermillion(VRML):Novel Diagnostic Tests Utilizing Biomarkers
Restructuring Play in Diagnostics at a VC Valuation Vermilion(VRML) technology utilizes a panel of biomarkers integrated with multivariate analysis software to develop disease specific assays. The...
Rayno Life Science Portfolio:Gen-Probe(GPRO) Files PMA Application for HPV
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that...
Cepheid (CPHD) GeneXpert TB Test in India
"A Deadly Misdiagnosis" by Michael Specter An interesting article in the November 15 New Yorker on the Tuberculosis epidemic in India stresses the need for more accurate diagnostic tests and how the...
Biomarkers and Blood Screening Tests: GenProbe (GPRO) and Genzyme(GENZ)
Here are some relevant news in areas that we previously covered: Biomarkers Genzyme (GENZ) licensed a lung cancer test under development to Roche and can target a patient's response to their Tarceva...
Market Ignores Bad News, Rallies on Retail Outlook
The market overcame bad news for Ireland and European debt, insider trading investigations , Korean crisis and a weak housing market for an S&P rally of 1.49%. NASDAQ is doing even better up...
Rayno Life Science Portfolio: Regeneron(REGN)up 14% on Eye Drug Phase 3 Results
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the...
Rayno Life Science Portfolio:Exelixis (EXEL) and Neogen (NEOG) Soar
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with...